Active, not recruitingPHASE2, PHASE3NCT05649748
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)
Studying Drug- or toxin-induced pulmonary arterial hypertension
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Insmed Incorporated
- Intervention
- Treprostinil Palmitil(drug)
- Enrollment
- 91 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2026
Study locations (30)
- USA005, Jacksonville, Florida, United States
- USA011, Tampa, Florida, United States
- USA006, Chicago, Illinois, United States
- USA001, Chicago, Illinois, United States
- USA102, New York, New York, United States
- USA016, Dallas, Texas, United States
- ARG009, Quilmes, Buenos Aires, Argentina
- ARG006, Rosario, Santa Fe Province, Argentina
- ARG007, San Miguel de Tucumán, Tucumán Province, Argentina
- ARG004, Córdoba, Argentina
- ARG001, Córdoba, Argentina
- AUT002, Linz, Upper Austria, Austria
- AUT001, Vienna, Austria
- BEL003, Brussels, Belgium
- BRA004, Belo Horizonte, Minas Gerais, Brazil
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05649748 on ClinicalTrials.govOther trials for Drug- or toxin-induced pulmonary arterial hypertension
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06872112A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial HypertensionJoseph C. Wu
- RECRUITINGPHASE2NCT06351345129 Xenon Imaging in Patients Treated With SotaterceptBastiaan Driehuys
- RECRUITINGPHASE4NCT07140484Sotatercept in Pulmonary Arterial HypertensionUniversity of Alberta
- RECRUITINGPHASE2NCT07175038A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)AllRock Bio, Inc.
- RECRUITINGNCT07013149The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial HypertensionUniversity of Sao Paulo General Hospital
- RECRUITINGNCT06998329PulmonAry hyperteNsion DiagnOsis: a National cohoRt reseArchUniversity of Sao Paulo General Hospital
- ENROLLING BY INVITATIONPHASE2NCT06992440Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial HypertensionGustavo A Heresi, MD, MS
- RECRUITINGNANCT06968962Comparison of Sequential to Initial Combination Therapy in PAHSecond Affiliated Hospital, School of Medicine, Zhejiang University
See all trials for Drug- or toxin-induced pulmonary arterial hypertension →